Radiotherapy combined with PD-1/PD-L1 antibody drugs has achieved significant success in malignant melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and some solid tumors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.